Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.

about

Clinical development of mTor inhibitors for renal cancer.

P2860

Q47737687-BDD61DB6-E973-40E3-9D17-7D8D3AE11B98

P2860

Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.

Item

http://www.wikidata.org/entity/Q38624864

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Optimal treatment of poor-risk ...... ibitors and anti-VEGFR agents.

@en

type

Item

label

Optimal treatment of poor-risk ...... ibitors and anti-VEGFR agents.

@en

prefLabel

Optimal treatment of poor-risk ...... ibitors and anti-VEGFR agents.

@en

P1476

Optimal treatment of poor-risk ...... ibitors and anti-VEGFR agents.

@en

P2093

Andrea Coinu

http://www.w3.org/2001/XMLSchema#string

Fausto Petrelli

http://www.w3.org/2001/XMLSchema#string

Sandro Barni

http://www.w3.org/2001/XMLSchema#string

P2860

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.

Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Post-treatment neutrophil-to-lymphocyte ratio in predicting prognosis in patients with metastatic clear cell renal cell carcinoma receiving sunitinib as first line therapy.

Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model.

P304

33-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.2016.1109454

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283501515

http://www.w3.org/2001/XMLSchema#string

P698

26535485

http://www.w3.org/2001/XMLSchema#string

Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.

about

P2860

P2860

Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698